Holen Sie sich die Stockscreener-App
41.79
0.65%
0.27
Schlusskurs vom Vortag:
$41.52
Offen:
$41.19
24-Stunden-Volumen:
1.05M
Relative Volume:
1.17
Marktkapitalisierung:
$3.37B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-64.16M
KGV:
-32.90
EPS:
-1.2702
Netto-Cashflow:
$-69.06M
1W Leistung:
+4.89%
1M Leistung:
+1.02%
6M Leistung:
+56.63%
1J Leistung:
+44.25%
1-Tages-Spanne:
$40.80
$42.10
1-Wochen-Bereich:
$39.28
$42.10
52-Wochen-Spanne:
$14.80
$46.01
Cg Oncology Inc Stock (CGON) Company Profile
Firmenname
Cg Oncology Inc
Sektor
Branche
Telefon
(949) 419-6203
Adresse
400 SPECTRUM CENTER DRIVE, IRVINE
Vergleichen Sie CGON mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
41.79 | 3.35B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-11 | Eingeleitet | Wedbush | Outperform |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-10-08 | Eingeleitet | Guggenheim | Buy |
| 2025-08-19 | Eingeleitet | Piper Sandler | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-05-02 | Eingeleitet | JP Morgan | Overweight |
| 2025-04-16 | Eingeleitet | Scotiabank | Sector Perform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-10-24 | Eingeleitet | UBS | Buy |
| 2024-09-23 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-08-28 | Eingeleitet | ROTH MKM | Buy |
| 2024-06-28 | Eingeleitet | BofA Securities | Buy |
| 2024-02-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-02-20 | Eingeleitet | Goldman | Neutral |
| 2024-02-20 | Eingeleitet | Morgan Stanley | Overweight |
| 2024-02-14 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Cg Oncology Inc Aktie (CGON) Neueste Nachrichten
Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
enGene Holdings: A Potential Oncology Entrant (NASDAQ:ENGN) - Seeking Alpha
CG Oncology Earnings Notes - Trefis
CG Oncology Appoints Christina Rossi to Board - MSN
CG Oncology Undervalued Going Into A Busy 2026 (NASDAQ:CGON) - Seeking Alpha
CG Oncology (CGON): Differentiated NMIBC Profile and Broad Market Strategy Support Upside and Buy Rating - TipRanks
SUO-CTC CG Oncology NMIBC Research Fellowship - Oncodaily
Will CG Oncology Inc. stock continue upward momentum2025 Geopolitical Influence & Advanced Technical Signal Analysis - Улправда
CG Oncology (CGON) Is Down 8.7% After Strong Cretostimogene NMIBC DataWhat's Changed - Sahm
Why CG Oncology Inc. stock is in analyst buy zoneMarket Rally & Real-Time Volume Trigger Notifications - DonanımHaber
Why analysts upgrade CG Oncology Inc. stock2025 Technical Overview & Precise Swing Trade Alerts - Улправда
Is CG Oncology Inc. stock supported by strong cash flows2025 Historical Comparison & Fast Entry High Yield Tips - Улправда
Will CG Oncology Inc. stock beat EPS estimatesJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Aug Summary: Why analysts upgrade CG Oncology Inc. stockChart Signals & Weekly High Return Opportunities - Улправда
Is CG Oncology Inc. stock a safe investment in uncertain marketsGold Moves & Low Risk Growth Stock Ideas - Улправда
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
SUO-CTC and CG Oncology Announce the Second Annual - GlobeNewswire
CG Oncology, Inc. (NASDAQ:CGON) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
CG Oncology Inc Stock Analysis and ForecastHigh Yield Income Stocks & Technical + Fundamental = Smarter Investing - earlytimes.in
CG Oncology appoints Rossi to its Board of Directors - MSN
OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases Shares of 26,000 CG Oncology, Inc. $CGON - MarketBeat
CG Oncology (NASDAQ:CGON) Earns Outperform Rating from Analysts at Wedbush - MarketBeat
CG Oncology initiated with an Outperform at Wedbush - TipRanks
Wedbush initiates coverage on CG Oncology stock with Outperform rating By Investing.com - Investing.com Canada
How Positive Cretostimogene Trial Updates And Leadership Moves At CG Oncology (CGON) Have Changed Its Investment Story - Yahoo Finance
CG Oncology, Inc. (CGON) is a Buy on Cancer Treatment Development: Truist Securities - Insider Monkey
CG Oncology (CGON) Valuation Check After Strong Late-Breaking Cretostimogene Bladder Cancer Trial Results - Sahm
Promising Prospects for CG Oncology, Inc.: Buy Rating Backed by Cretostimogene’s Potential in NMIBC Market - TipRanks
CG Oncology (NASDAQ:CGON) Sets New 1-Year HighStill a Buy? - MarketBeat
Cg Oncology Inc. (CGON) Live Share Price, Invest From India - INDmoney
CG Oncology, Inc. (CGON) stock price, news, quote and history - Yahoo Finance UK
CG Oncology Incannounced topline data from Bond-003 cohort P and first results from Core-008 cohort A - marketscreener.com
New Cretostimogene Grenadenorepvec Data Highlight its Potential to Become the Backbone Therapy for High-Risk Non-Muscle Invasive Bladder Cancer - The Manila Times
CG Oncology Reports Promising Efficacy and Safety Data for Cretostimogene in High-Risk Non-Muscle Invasive Bladder Cancer Trials - Quiver Quantitative
CG Oncology (NASDAQ: CGON) posts 83.7% CR, no Grade 3+ AEs in NMIBC trial data - Stock Titan
Schroder Investment Management Group Acquires 155,737 Shares of CG Oncology, Inc. $CGON - MarketBeat
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC - Urology Times
Will CG Oncology’s (CGON) Board Refresh and Cretostimogene Data Shape Its Bladder Cancer Strategy? - Sahm
Muscle Invasive Bladder Cancer Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, LLC, Protara Therapeutics, Binhui Biopharma - The Globe and Mail
Muscle Invasive Bladder Cancer Market to Reach New Heights - openPR.com
Midday Stock Roundup: Tilly’s, indie Semiconductor Up - Orange County Business Journal
CG Oncology (CGON) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
CG Oncology Appoints Jim DeTore as Interim CFO - MSN
FY2025 EPS Estimates for CG Oncology Increased by Analyst - MarketBeat
A Look at CG Oncology's (CGON) Valuation Following New Clinical Trial Data Announcements - Sahm
Guidance Update: Will CG Oncology Inc. stock beat EPS estimates2025 Key Lessons & Proven Capital Preservation Tips - moha.gov.vn
Tejara Capital Ltd Purchases New Position in CG Oncology, Inc. $CGON - MarketBeat
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
Intech Investment Management LLC Acquires 6,503 Shares of CG Oncology, Inc. $CGON - MarketBeat
CG Oncology, Inc. $CGON Shares Purchased by Franklin Resources Inc. - MarketBeat
Geode Capital Management LLC Increases Stake in CG Oncology, Inc. $CGON - MarketBeat
Finanzdaten der Cg Oncology Inc-Aktie (CGON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):